Cationic steroidal antimicrobials
Disclosed herein are cationic steroidal antimicrobials (“CSA compounds” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSA compounds.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is optionally substituted C 11-22 -alkylester-C x -alkyl;
R 2 , R 3 , and R 4 , are independently selected from the group consisting of optionally substituted amino-C a -alkyl and optionally substituted amino-C a -alkylcarbonyl;
x is 1-5; and
a is 2-5.
2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 1 is an optionally substituted C 11 -alkylester-C x -alkyl.
3. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 1 is an optionally substituted C 12-22 -alkylester-C x -alkyl.
4. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein the ester is a carboxylic ester selected from oxycarbonyl or carbonyloxy.
5. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein x is 2.
6. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein x is 3.
7. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein x is 4.
8. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein x is 5.
9. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein two or three of R 2 , R 3 , and R 4 are the same.
10. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 2 , R 3 , and R 4 are all different.
11. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein a is 2.
12. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein a is 3.
13. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein a is 4.
14. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein a is 5.
15. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 2 , R 3 , and R 4 are optionally substituted amino-C a -alkyl.
16. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 2 , R 3 , and R 4 are optionally substituted amino-C a -alkylcarbonyl.
17. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein one or more of R 1 , R 2 , R 3 , and R 4 is unsubstituted.
18. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein two or more of R 1 , R 2 , R 3 , and R 4 are unsubstituted.
19. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein three or more of R 1 , R 2 , R 3 , and R 4 are unsubstituted.
20. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein R 1 , R 2 , R 3 , and R 4 are unsubstituted.
21. A pharmaceutical composition comprising at one compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 and a pharmaceutically acceptable excipient.
22. The pharmaceutical composition as in claim 21 , wherein the pharmaceutically acceptable excipient is a liquid or a solid.
23. A composition of matter comprising at one compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 and at least one carrier.
24. The composition of matter as in claim 23 , wherein the carrier is a liquid or a solid.
25. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
26. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein the pharmaceutically acceptable salt of the compound of Formula (I) is an acid addition salt of sulfuric acid, nitric acid, phosphoric acid, organic acid, carboxylic acid, or sulfonic acid.
27. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein the pharmaceutically acceptable salt of the compound of Formula (I) is an acid addition of a carboxylic acid selected from the group consisting of formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, malonic acid, maleic acid, fumaric acid, trifluoroacetic acid, benzoic acid, cinnamic acid, mandelic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, and valproic acid.
28. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as in claim 1 , wherein the pharmaceutically acceptable salt of the compound of Formula (I) is an acid addition of a sulfonic acid selected from the group consisting of methanesulfonic acid, ethanesulfonic acid, p-toluensulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, and naphthalenesulfonic acid.